These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 22242932)

  • 1. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes.
    Xu XS; Moore K; Burton P; Stuyckens K; Mueck W; Rossenu S; Plotnikov A; Gibson M; Vermeulen A
    Br J Clin Pharmacol; 2012 Jul; 74(1):86-97. PubMed ID: 22242932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.
    Mueck W; Lensing AW; Agnelli G; Decousus H; Prandoni P; Misselwitz F
    Clin Pharmacokinet; 2011 Oct; 50(10):675-86. PubMed ID: 21895039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.
    Mueck W; Eriksson BI; Bauer KA; Borris L; Dahl OE; Fisher WD; Gent M; Haas S; Huisman MV; Kakkar AK; Kälebo P; Kwong LM; Misselwitz F; Turpie AG
    Clin Pharmacokinet; 2008; 47(3):203-16. PubMed ID: 18307374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.
    Mueck W; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Kälebo P; Muelhofer E; Misselwitz F; Eriksson BI
    Thromb Haemost; 2008 Sep; 100(3):453-61. PubMed ID: 18766262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects.
    Mueck W; Becka M; Kubitza D; Voith B; Zuehlsdorf M
    Int J Clin Pharmacol Ther; 2007 Jun; 45(6):335-44. PubMed ID: 17595891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.
    Girgis IG; Patel MR; Peters GR; Moore KT; Mahaffey KW; Nessel CC; Halperin JL; Califf RM; Fox KA; Becker RC
    J Clin Pharmacol; 2014 Aug; 54(8):917-27. PubMed ID: 24668660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes.
    Gopalakrishnan L; Kumar V; Kohli P; Singh P; Rastogi U; Gibson CM
    Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):889-900. PubMed ID: 22577900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].
    Ordovás Baines JP; Climent Grana E; Jover Botella A; Valero García I
    Farm Hosp; 2009; 33(3):125-33. PubMed ID: 19712596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban population pharmacokinetic and pharmacodynamic modeling in Iranian patients.
    Esmaeili T; Rezaee M; Abdar Esfahani M; Davoudian A; Omidfar D; Rezaee S
    J Clin Pharm Ther; 2022 Aug; 47(8):1284-1292. PubMed ID: 35504629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor.
    Kubitza D; Becka M; Roth A; Mueck W
    J Clin Pharmacol; 2013 Mar; 53(3):249-55. PubMed ID: 23381840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation.
    Tanigawa T; Kaneko M; Hashizume K; Kajikawa M; Ueda H; Tajiri M; Paolini JF; Mueck W
    Drug Metab Pharmacokinet; 2013; 28(1):59-70. PubMed ID: 22813718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
    Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E
    Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor.
    Kubitza D; Roth A; Becka M; Alatrach A; Halabi A; Hinrichsen H; Mueck W
    Br J Clin Pharmacol; 2013 Jul; 76(1):89-98. PubMed ID: 23294275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban.
    Mueck W; Stampfuss J; Kubitza D; Becka M
    Clin Pharmacokinet; 2014 Jan; 53(1):1-16. PubMed ID: 23999929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation.
    Liu XQ; Zhang YF; Ding HY; Yan MM; Jiao Z; Zhong MK; Ma CL
    Acta Pharmacol Sin; 2022 Oct; 43(10):2723-2734. PubMed ID: 35354961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor.
    Kreutz R
    Curr Clin Pharmacol; 2014 Feb; 9(1):75-83. PubMed ID: 24218999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel oral anticoagulants in acute coronary syndrome.
    Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
    Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51).
    Mega JL; Braunwald E; Murphy SA; Plotnikov AN; Burton P; Kiss RG; Parkhomenko A; Tendera M; Widimsky P; Gibson CM
    J Am Coll Cardiol; 2013 May; 61(18):1853-9. PubMed ID: 23500262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic and pharmacokinetic basics of rivaroxaban.
    Kreutz R
    Fundam Clin Pharmacol; 2012 Feb; 26(1):27-32. PubMed ID: 21848931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.
    Willmann S; Becker C; Burghaus R; Coboeken K; Edginton A; Lippert J; Siegmund HU; Thelen K; Mück W
    Clin Pharmacokinet; 2014 Jan; 53(1):89-102. PubMed ID: 23912563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.